Aspergillosis is a group of diseases that occur from aspergillus infection. Aspergillus is a fungus whose spores are present in the air, but does not normally cause illness. Individuals with damaged lungs, sensitive immune system, and allergies are more prone to aspergillus induced infection. Common aspergillus infections include invasive aspergillosis, non-invasive Allergic Pulmonary Aspergillosis (ABPA), and Chronic Pulmonary Aspergilloma (CPA). Azoles are the only oral drug with anti-aspergillus activity and itraconazole and voriconazole are considered as first-line drugs for chronic pulmonary aspergillosis.
Market Dynamics
Key players operating in the market are focusing on development and approval of novel therapeutics for the treatment of chronic aspergillosis, which is expected to offer a lucrative opportunity to the market players to launch innovative products in the market for the treatment of aspergillosis. For instance, In October 2017, Mylan N.V. launched caspofungin acetate for injection, one of the first generic versions of the U.S. pharma giant Merck's & Co’s Cancidas. It is indicated for invasive aspergillosis in patients who are refractory to or intolerant of other therapies. Furthermore, key companies in the market focusing on growth strategies such as FDA approvals which is expected to drive the growth of the market over forecast period. For instance, In January 2020, PULMATRiX, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation to PUR1900 (Pulmazole). The company's inhaled itraconazole antifungal candidate is developed to treat allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.
Key features of the study:
- This report provides in-depth analysis of the global chronic aspergillosis treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global chronic aspergillosis treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Astellas Pharma Inc., Abbott Laboratories, Pfizer Inc., Pulmocide Ltd., Johnson & Johnson, Mylan N.V., Glenmark Pharmaceuticals, Merck & Co., Inc., Mayne Pharma Group Limited, GlaxoSmithKline plc., PULMATRiX, Inc., F2G Ltd, Teva Pharmaceutical Industries Ltd., and Novartis International AG
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global chronic aspergillosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic aspergillosis treatment market
Detailed Segmentation:
- Global Chronic Aspergillosis Treatment Market, By Drug Class :
- Corticosteroids
- Anti-fungal Drugs
- Global Chronic Aspergillosis Treatment Market, By Disease Type :
- Simple Aspergilloma
- Chronic Cavitary Pulmonary Aspergillosis
- Chronic Fibrosing Pulmonary Aspergillosis
- Subacute Invasive Aspergillosis
- Allergic Bronchopulmonary Aspergillosis [ABPA]
- Severe Asthma With Fungal Sensitization [SAFS]
- Global Chronic Aspergillosis Treatment Market, By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies and Drug Store
- E-commerce
- Global Chronic Aspergillosis Treatment Market, By Region:
- North America
- By Drug Class
- Corticosteroids
- Anti-fungal Drugs
- By Disease Type
- Simple Aspergilloma
- Chronic Cavitary Pulmonary Aspergillosis
- Chronic Fibrosing Pulmonary Aspergillosis
- Subacute Invasive Aspergillosis
- Allergic Bronchopulmonary Aspergillosis [ABPA]
- Severe Asthma With Fungal Sensitization [SAFS]
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies and Drug Store
- E-commerce
- By Country
- Latin America
- By Drug Class
- Corticosteroids
- Anti-fungal Drugs
- By Disease Type
- Simple Aspergilloma
- Chronic Cavitary Pulmonary Aspergillosis
- Chronic Fibrosing Pulmonary Aspergillosis
- Subacute Invasive Aspergillosis
- Allergic Bronchopulmonary Aspergillosis [ABPA]
- Severe Asthma With Fungal Sensitization [SAFS]
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies and Drug Store
- E-commerce
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Class
- Corticosteroids
- Anti-fungal Drugs
- By Disease Type
- Simple Aspergilloma
- Chronic Cavitary Pulmonary Aspergillosis
- Chronic Fibrosing Pulmonary Aspergillosis
- Subacute Invasive Aspergillosis
- Allergic Bronchopulmonary Aspergillosis [ABPA]
- Severe Asthma With Fungal Sensitization [SAFS]
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies and Drug Store
- E-commerce
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Class
- Corticosteroids
- Anti-fungal Drugs
- By Disease Type
- Simple Aspergilloma
- Chronic Cavitary Pulmonary Aspergillosis
- Chronic Fibrosing Pulmonary Aspergillosis
- Subacute Invasive Aspergillosis
- Allergic Bronchopulmonary Aspergillosis [ABPA]
- Severe Asthma With Fungal Sensitization [SAFS]
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies and Drug Store
- E-commerce
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug Class
- Corticosteroids
- Anti-fungal Drugs
- By Disease Type
- Simple Aspergilloma
- Chronic Cavitary Pulmonary Aspergillosis
- Chronic Fibrosing Pulmonary Aspergillosis
- Subacute Invasive Aspergillosis
- Allergic Bronchopulmonary Aspergillosis [ABPA]
- Severe Asthma With Fungal Sensitization [SAFS]
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies and Drug Store
- E-commerce
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Class
- Corticosteroids
- Anti-fungal Drugs
- By Disease Type
- Simple Aspergilloma
- Chronic Cavitary Pulmonary Aspergillosis
- Chronic Fibrosing Pulmonary Aspergillosis
- Subacute Invasive Aspergillosis
- Allergic Bronchopulmonary Aspergillosis [ABPA]
- Severe Asthma With Fungal Sensitization [SAFS]
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies and Drug Store
- E-commerce
- By Region/Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Astellas Pharma Inc.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Abbott Laboratories
- Pfizer Inc.
- Pulmocide Ltd.
- Johnson & Johnson
- Mylan N.V.
- Glenmark Pharmaceuticals
- Merck & Co., Inc.
- Mayne Pharma Group Limited
- GlaxoSmithKline plc.
- PULMATRiX, Inc.
- F2G Ltd
- Teva Pharmaceutical Industries Ltd.
- Novartis International AG
“*” marked represents similar segmentation in other categories in the respective section.
